1 Objectives: Weekly monitoring of European all-cause excess mortality, the EuroMOMO 2 network, observed high excess mortality during the influenza B/Yamagata dominated 3 2017/18 winter season, especially among elderly. We describe all-cause excess and 4 influenza-attributable mortality during the season 2017/18 in Europe. 5 Methods: Based on weekly reporting of mortality from 24 European countries or sub-6 national regions, representing 60% of the European population excl. Russia and the Turkey 7 part of European, we estimated age stratified all-cause excess morality using the 8 EuroMOMO model. In addition, age stratified all-cause influenza-attributable mortality was 9 estimated using the FluMOMO algorithm, incorporating influenza activity based on clinical 10 and virological surveillance data, and adjusting for extreme temperatures.
Mortality in temperate countries, in particular among senior citizens, exhibits a marked 27 seasonality, with higher mortality in the winter period. Excess mortality may vary 28 considerably between countries and from season to season (1-7). One of the main drivers stratified pooled analyses of these data (10) . We estimated the pooled excess mortality for 1 the winter season 2017/18 using all-cause mortality data from week 1/2014 to week 2 20/2018, from 24 participating national or sub-nation states (Austria, Belgium, Berlin 3 (Germany), Denmark, England (UK), Estonia, Finland, France, Greece, Hesse (Germany), 4 Hungary, Ireland, Italy, Luxembourg, Malta, Netherlands, Northern Ireland (UK), Norway, 5 Portugal, Scotland (UK), Spain, Sweden, Switzerland, Wales (UK)), further on referred to as 6 countries.
7
Mortality data reported to the EuroMOMO hub in week 27/2018 were used. 
Results

11
Overall, the European 2017/18 influenza season was dominated by influenza B (Figure 1 ).
12
The weekly influenza PP was nearly two times higher for influenza B than influenza A, 13 however with some variation between the participating countries. Seasonal influenza causes a major health burden (21), especially for the elderly and 24 persons with underlying health conditions. In addition to the direct effects of influenza 25 infection, underlying health conditions may be exacerbated leading to poor health outcomes 26 and even premature death. In this situation, influenza or respiratory tract infection may not 27 be registered as cause of death. Hence, estimates of influenza-attributable mortality based 28 on all-cause rather than cause-specific mortality e.g. respiratory deaths including influenza 29 and pneumonia, is expected to be higher. Influenza-attributable deaths coded as non-30 respiratory deaths have been found to be at the same magnitude as for respiratory 31 influenza mortality (22, 23) . Therefore, all-cause mortality attributable to influenza may be 32 expected to be around the double of influenza mortality based on respiratory cause of death
outcomes, and do not consider indirect protection and herd immunity. However, even 1 though influenza B/Yamagata was not included in the 2017/18 season's trivalent influenza 2 vaccine, which was most widely used in European countries, the vaccine effectiveness 3 against influenza B has been estimated to 36-54% (30), maybe due to preserved immunity 4 from previous immunisation (infection or vaccination) (31) or cross protection. 14 All analyses of influenza-attributable mortality were performed at the EuroMOMO hub, 15 using IA data from TESSy. This has the advantage of using common, standardised IA data, 16 but also has limitations e.g. missing a local review and validation process.
17
The Goldstein Index: ILI x PP, represents the most conservative indicator of influenza 18 activity and was the IA indicator used in the FluMOMO model (7, 14) . However, not all 19 countries report ILI, and we used ARI or Intensity, where ILI was unavailable. Further, 20 virology data from TESSy were not age-stratified; hence, the same all-ages-PP was used in 21 each of the age groups, which may have masked differences between age groups. The 22 impact of these limitations in IA should be investigated.
23
Mortality attributable to influenza differentiated by type/sub-type may provide an improved 24 understanding of the burden attributable to each type/sub-type. However, the nearly equal 25 pattern in the circulation of influenza A and B in the 2017/18 season (Figure 1) introduced 26 collinearity between the influenza types i.e. making the effects difficult to separate. Further, 27 splitting the IA parameter into type/sub-type substantially reduced the statistical power 28 making the model unstable. Therefore, it was not feasible to make type/sub-type 29 differentiated estimates.
30
Heterogeneity in mortality patterns between countries may reflect some real differences, 31 possibly related to differences in influenza circulation by type/sub-type, country-specific 32 population susceptibility, differences in influenza vaccine uptake, varying from 5 to 75% 33 coverage among elderly (32), or vaccine effectiveness. Therefore, regional analyses have 
